



Erratum to the effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Zheyong Huang^{1#}, Ji Tian Cao^{1#}, Yumeng Yao², Xuejuan Jin¹, Zhe Luo³, Yuan Xue³, Chouwen Zhu⁴, Yanan Song¹, Ying Wang¹, Yunzeng Zou¹, Juying Qian¹, Kaihuan Yu⁵, Hui Gong¹, Junbo Ge¹

¹Shanghai Institute of Cardiovascular Diseases, ²Department of Infection Disease, ³Department of Critical Medicine, ⁴Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China; ⁵Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China

[#]These authors contributed equally to this work.

Correspondence to: Hui Gong, PhD and Junbo Ge, MD, PhD. Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, China. Email: gonghui2005@fudan.edu.cn; junboge@126.com.

doi: 10.21037/atm-2020-27

View this article at: <http://dx.doi.org/10.21037/atm-2020-27>

Erratum to: *Ann Transl Med* 2020;8:430

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

In the article entitled “The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension (1), there are some errors. In *Table 2*, the data about in hospital mortality should be deleted, because the correct data about in hospital mortality have been showed in *Table 6*. The *Table 2* should be replaced by the following table.

Table 2 Comparison of demographic and clinical characteristics of patients with COVID-19 between Group A (including RAS blockers treatment) and Group B (non-RAS blockers treatment)

	Group A (n=20)	Group B (n=30)	P value
Age (yrs, mean \pm SD)	52.65 \pm 13.12	67.77 \pm 12.84	0.000
Age \geq 65, n (%)	4 (20)	19 (63.33)	0.003
Male gender, n (%)	10 (50)	17 (56.67)	0.643
Underlying disease, n (%)			0.140
Diabetes mellitus	0 (0)	4 (13.33)	
CAD	0 (0)	1 (3.33)	
COPD	1 (5)	0 (0)	
Anemia	1 (5)	0 (0)	
Time since disease onset (days)	13.25 \pm 2.17	15.17 \pm 4.05	0.059
Highest temperature ($^{\circ}$ C)	38.54 \pm 0.84	38.13 \pm 1.01	0.140
Symptoms, n (%)			
Fever	19 (95)	28 (93.33)	1.000
Cough	13 (65)	20 (66.67)	0.903
Expectoration	2 (10)	8 (26.67)	0.149
Dyspnea	3 (15)	9 (30)	0.371
Diarrhoea	3 (15)	3 (10)	0.672
Muscle ache	2 (10)	4 (13.33)	1.000
Fatigue	9 (45)	9 (30)	0.279
Anorexia	4 (20)	5 (16.67)	1.000
Vital signs			
Heart rate (bpm)	88.65 \pm 18.25	85.1 \pm 14.22	0.444
Respiratory rate (breaths per minute)	20.2 \pm 3.89	20.87 \pm 4.48	0.590
Systolic BP (mmHg)	124.9 \pm 17.24	128.5 \pm 19.55	0.507
Diastolic BP (mmHg)	77.25 \pm 12.48	77.83 \pm 12.3	0.871
Clinical severity, n (%)			0.227
Mild-moderate	7 (35)	6 (20)	
Severe	12 (60)	18 (60)	
Critically ill	1 (5)	6 (20)	

Data are expressed as mean \pm SD or number (%); P values denoted the comparison between A and B subgroups. COVID-19, coronavirus disease 2019; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; BP, blood pressure.

We regret the errors.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited

(including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Huang Z, Cao J, Yao Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. *Ann Transl Med* 2020;8:430.

Cite this article as: Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, Zhu C, Song Y, Wang Y, Zou Y, Qian J, Yu K, Gong H, Ge J. Erratum to the effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. *Ann Transl Med* 2020;8(17):1119. doi: 10.21037/atm-2020-27